Ferric Carboxymaltose to Improve Skeletal Muscle Metabolism in Heart Failure Patients With Functional Iron Deficiency

Iron-deficiency Clinical Trial

Official title:

Ferric Carboxymaltose to Improve Skeletal Muscle Metabolism in Heart Failure Patients With Functional Iron Deficiency

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT03218384
• Other study ID #: 17-00444
• Status: Terminated
• Phase: Phase 2
• Start date: September 7, 2017
• Est. completion date: April 4, 2022

Study information

• Verified date: June 2023
• Source: NYU Langone Health
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to better understand how body levels of iron affect the ability to exercise in patients with heart failure (HF).

Heart failure is a condition in which abnormal pumping action of the heart reduces the flow of blood to the body. Patients with heart failure may feel shortness of breath or leg fatigue when they exercise. Iron is an essential nutrient in the diet. In heart failure patients, low body levels of iron might increase shortness of breath and fatigue.

Description:

The purpose of this prospective, double blind parallel group randomized study is to compare the effects of ferric carboxymaltose vs. placebo on skeletal muscle mitochondrial oxidative capacity, submaximal exercise tolerance, and health-related quality of life in non-anemic Heart Failure (HF) patients with functional iron deficiency.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 20
• Est. completion date: April 4, 2022
• Est. primary completion date: April 4, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 21 Years to 75 Years

Eligibility

Inclusion Criteria:

• Symptomatic NYHA Class II-III heart failure >3 months

• Guideline-recommended heart failure treatment for > 3 months

• Hemoglobin >13 g/dl for men and >12 g/dl for women

• Functional iron deficiency (defined as serum ferritin level <100 ng/ml or between 100 and 299 ng/ml with transferrin saturation <20%)

• Left ventricular ejection fraction <40%, or left ventricular ejection fraction =40% with left atrial enlargement (left atrial volume index >28 ml/m2) and/or left ventricular hypertrophy (left ventricular mass index >95 g/m2 (women) or >115 g/m2 (men) determined by echocardiogram within last 24 months.

• Able and willing to provide written informed consent

Exclusion Criteria:

• Presence of implantable defibrillator, permanent pacemaker, other metal implant not compatible with 3TMRS/MRI, or other contraindication to 3T MRS/MRI procedures

• Heart failure due to infiltrative cardiomyopathy, restrictive cardiomyopathy, or hypertrophic cardiomyopathy

• Weight <50 kg or >120 kg

• Coronary or cerebral atherothrombotic events in the past 6 months

• Hospitalization of emergency room visit for heart failure within past 3 months

• ICD shock in last 3 months

• Known peripheral artery disease or ankle-brachial index <0.9 at screening visit

• Exercise primarily limited by angina, lung disease or neuromuscular disease

• Systolic blood pressure <100 or >160 mmHg

• Heart rate <50 or >110 min-1

• Estimated glomerular filtration rate <30 ml/min

• Liver function tests >3 times upper limit of normal

• Serum phosphate below normal limit

• Pregnant or breast-feeding women

• Women of child-bearing potential unwilling to use recommended contraception methods during the study

• Treatment with oral iron supplements (except multivitamins) in past year

• Treatment with intravenous iron in past year

• Treatment with erythropoiesis stimulating agents in the past year

• Known intolerance of intravenous iron

• History of anaphylaxis

• Participation in another clinical trial within last 30 days.

Related Conditions & MeSH terms

• Anemia, Iron-Deficiency
• Heart Failure
• Iron-deficiency

Intervention

Drug:
• Ferric Carboxymaltose
Intravenous Ferric Carboxymaltose 750 mg mixed under sterile conditions in 100 ml of normal saline for final concentration of 7.5 mg/ml and administered via volumetric infusion pump over 15 minutes.
• Placebo
100 ml of normal saline solution, and administered via volumetric infusion pump over 15 minutes.

Device:
• 31P MRS/MRI
Each participant will perform the same rhythmic plantar extension exercise protocol twice, for sequential acquisition of magnetic resonance spectroscopy (MRS) and magnetic resonance imaging (MRI) measurements. For the exercise protocol, the participant will lay supine on the scanning table with the right leg inside the volume coil. The exercise consists of repeated plantar flexion movements using resistance bands at a frequency of one repetition per second for 1-2 minutes. Data are collected continuously for 2 minutes before the exercise (baseline), during exercise, and 5 minutes after the exercise for the MRS and MRI experiments.

Locations

Country	Name	City	State
United States	New York University School of Medicine	New York	New York

Sponsors (1)

Lead Sponsor	Collaborator
NYU Langone Health

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change From Baseline in Post-Exercise Phosphocreatine Recovery Time	Post-exercise phosphocreatine recovery time (in seconds) will be used to assess mitochondrial oxidative capacity. It is measured non-invasively with 31P-magnetic resonance spectroscopy.	Baseline, Week 4
Secondary	Change From Baseline in 6-Minute Walk Test Distance	The 6-minute walk test measures the distance that a patient can walk on a flat, hard surface in a period of 6 minutes.	Baseline, Week 4
Secondary	Change From Baseline in Kansas City Cardiomyopathy Questionnaire Score	23-item self-assessment of symptoms, physical and social limitations, and quality of life in patients with heart failure. KCCQ responses are provided along a rating scale continuum with equal spacing from worst to best. The total score ranges from 0-100, with higher scores indicating better health status. An increase in scores indicates health status improved during the observational period.	Baseline, Week 4
Secondary	Change From Baseline in Hemoglobin Levels	Hemoglobin is a protein in red blood cells that carries oxygen. Hemoglobin levels (g/dL) were measured in laboratory analyses using patient blood samples.	Baseline, Week 4
Secondary	Change From Baseline in Serum Ferritin Levels	Ferritin is a blood protein that contains iron. Serum ferritin levels (ng/ml) were measured in laboratory analyses using patient blood samples.	Baseline, Week 4
Secondary	Change From Baseline in Transferrin Saturation	Transferrin saturation, measured as a percentage, is the value of serum iron divided by the total iron-binding capacity of the available transferrin. Transferrin saturation was measured in laboratory analyses using patient blood samples.	Baseline, Week 4